These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 38373532)
21. Repurposing Molnupiravir for COVID-19: The Mechanisms of Antiviral Activity. Yip AJW; Low ZY; Chow VTK; Lal SK Viruses; 2022 Jun; 14(6):. PubMed ID: 35746815 [TBL] [Abstract][Full Text] [Related]
22. Replication of Human Norovirus in Human Intestinal Enteroids Is Affected by Fecal Sample Processing. Narwankar R; Esseili MA Viruses; 2024 Feb; 16(2):. PubMed ID: 38400017 [TBL] [Abstract][Full Text] [Related]
23. Feasibility of Polyclonal Avian Immunoglobulins (IgY) as Prophylaxis against Human Norovirus Infection. Artman C; Idegwu N; Brumfield KD; Lai K; Hauta S; Falzarano D; Parreño V; Yuan L; Geyer JD; Goepp JG Viruses; 2022 Oct; 14(11):. PubMed ID: 36366469 [TBL] [Abstract][Full Text] [Related]
24. Optimizing Human Intestinal Enteroids for Environmental Monitoring of Human Norovirus. Overbey KN; Zachos NC; Coulter C; Schwab KJ Food Environ Virol; 2021 Dec; 13(4):470-484. PubMed ID: 34191266 [TBL] [Abstract][Full Text] [Related]
25. Human norovirus cultivation systems and their use in antiviral research. Hayashi T; Kobayashi S; Hirano J; Murakami K J Virol; 2024 Apr; 98(4):e0166323. PubMed ID: 38470106 [TBL] [Abstract][Full Text] [Related]
26. Favipiravir induces HuNoV viral mutagenesis and infectivity loss with clinical improvement in immunocompromised patients. Kreins AY; Roux E; Pang J; Cheng I; Charles O; Roy S; Mohammed R; Owens S; Lowe DM; Brugha R; Williams R; Howley E; Best T; Davies EG; Worth A; Solas C; Standing JF; Goldstein RA; Rocha-Pereira J; Breuer J Clin Immunol; 2024 Feb; 259():109901. PubMed ID: 38218209 [TBL] [Abstract][Full Text] [Related]
27. Human intestinal enteroids platform to assess the infectivity of gastroenteritis viruses in wastewater. Carmona-Vicente N; Pandiscia A; Santiso-Bellón C; Perez-Cataluña A; Rodríguez-Díaz J; Costantini VP; Buesa J; Vinjé J; Sánchez G; Randazzo W Water Res; 2024 May; 255():121481. PubMed ID: 38520776 [TBL] [Abstract][Full Text] [Related]
28. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir. Waters MD; Warren S; Hughes C; Lewis P; Zhang F Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215 [TBL] [Abstract][Full Text] [Related]
29. Post-exposure antiviral treatment of norovirus infections effectively protects against diarrhea and reduces virus shedding in the stool in a mortality mouse model. Rocha-Pereira J; Kolawole AO; Verbeken E; Wobus CE; Neyts J Antiviral Res; 2016 Aug; 132():76-84. PubMed ID: 27252124 [TBL] [Abstract][Full Text] [Related]
30. Viral polymerase binding and broad-spectrum antiviral activity of molnupiravir against human seasonal coronaviruses. Wang Y; Li P; Solanki K; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q Virology; 2021 Dec; 564():33-38. PubMed ID: 34619630 [TBL] [Abstract][Full Text] [Related]
31. β-d-N Konishi K; Kusakabe S; Kawaguchi N; Shishido T; Ito N; Harada M; Inoue S; Maeda K; Hall WW; Orba Y; Sawa H; Sasaki M; Sato A Antiviral Res; 2024 Sep; 229():105977. PubMed ID: 39089332 [TBL] [Abstract][Full Text] [Related]
32. Human Sapovirus Replication in Human Intestinal Enteroids. Euller-Nicolas G; Le Mennec C; Schaeffer J; Zeng XL; Ettayebi K; Atmar RL; Le Guyader FS; Estes MK; Desdouits M J Virol; 2023 Apr; 97(4):e0038323. PubMed ID: 37039654 [TBL] [Abstract][Full Text] [Related]
33. Bile acid-sensitive human norovirus strains are susceptible to sphingosine-1-phosphate receptor 2 inhibition. Tenge V; Vijayalakshmi Ayyar B; Ettayebi K; Crawford SE; Shen YT; Neill FH; Atmar RL; Estes MK bioRxiv; 2024 Jan; ():. PubMed ID: 38260626 [TBL] [Abstract][Full Text] [Related]
34. Histo-blood group antigens of glycosphingolipids predict susceptibility of human intestinal enteroids to norovirus infection. Rimkute I; Thorsteinsson K; Henricsson M; Tenge VR; Yu X; Lin SC; Haga K; Atmar RL; Lycke N; Nilsson J; Estes MK; Bally M; Larson G J Biol Chem; 2020 Nov; 295(47):15974-15987. PubMed ID: 32913124 [TBL] [Abstract][Full Text] [Related]
35. Molnupiravir: Mechanism of action, clinical, and translational science. Maas BM; Strizki J; Miller RR; Kumar S; Brown M; Johnson MG; Cheng M; De Anda C; Rizk ML; Stone JA Clin Transl Sci; 2024 Feb; 17(2):e13732. PubMed ID: 38593352 [TBL] [Abstract][Full Text] [Related]
36. Molnupiravir; molecular and functional descriptors of mitochondrial safety. Wallace KB; Bjork JA Toxicol Appl Pharmacol; 2022 May; 442():116003. PubMed ID: 35358570 [TBL] [Abstract][Full Text] [Related]
37. Changing pattern of prevalence and genetic diversity of rotavirus, norovirus, astrovirus, and bocavirus associated with childhood diarrhea in Asian Russia, 2009-2012. Zhirakovskaia E; Tikunov A; Tymentsev A; Sokolov S; Sedelnikova D; Tikunova N Infect Genet Evol; 2019 Jan; 67():167-182. PubMed ID: 30414977 [TBL] [Abstract][Full Text] [Related]
38. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. Gordon CJ; Tchesnokov EP; Schinazi RF; Götte M J Biol Chem; 2021 Jul; 297(1):100770. PubMed ID: 33989635 [TBL] [Abstract][Full Text] [Related]
39. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361 [TBL] [Abstract][Full Text] [Related]